Latest Small interfering RNA Stories
WESTBOROUGH, Mass., May 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies
Transparency Market Research Report Added "Research Report on Micro-RNA Market Analysis, Trends And Forecast, 2013 - 2019" to its database.
SAN DIEGO, Feb.
LA JOLLA, Calif., Feb.
A team of international researchers say “turning off” the gene for mesothelin slows the spread of mesothelioma and sensitizes cells to cisplatin therapy. Raleigh,
- Arcturus proprietary LUNAR(TM) delivery technology demonstrates exceptional potency in vivo, ED(50) of 0.020 mg/kg SAN DIEGO, Jan.
New Preclinical Results in Non-Human Primates Demonstrate Significant and Sustained Reduction of Transthyretin Using its Proprietary LUNARTM Delivery Technology SAN DIEGO, Jan.
SEATTLE, Jan. 10, 2014 /PRNewswire/ -- PhaseRx, Inc., an RNA therapeutics company, today announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development.
Scientists at the National Institutes of Health have used RNA interference (RNAi) technology to reveal dozens of genes which may represent new therapeutic targets for treating Parkinson's disease.
- The parings of haberdine; also, any kind of fragments.